Gulen Hatemi
Overview
Explore the profile of Gulen Hatemi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
2301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sulu B, Hatemi G
Arch Rheumatol
. 2025 Mar;
39(4):511-521.
PMID: 40060132
Behçet's syndrome is a variable vessel vasculitis characterized by a diverse range of clinical manifestations resulting from inflammation involving several organs and systems. While significant progress has been made in...
2.
Karakoc A, Ozguler Y, Ozdede A, Ferhatoglu Z, Yildiz K, Kutlubay Z, et al.
Semin Arthritis Rheum
. 2025 Feb;
71:152643.
PMID: 39929007
Introduction: Post-thrombotic syndrome (PTS) and stasis ulcers are late complications of deep vein thrombosis (DVT) in Behçet's syndrome (BS). We aimed to determine the clinical and histopathological characteristics, treatment modalities,...
3.
Sota J, Ragab G, AlMaglouth I, Lopalco G, Tufan A, Direskeneli H, et al.
Joint Bone Spine
. 2024 Nov;
92(2):105819.
PMID: 39549971
Objectives: Gender impact on phenotypical expression of Behçet's disease (BD) has been specifically investigated only in a few large-scale studies. The main goal of the study was to examine gender...
4.
Durak Ediboglu E, Cinar M, Kozaci D, Solmaz D, Sargin G, Karadag O, et al.
Eur J Rheumatol
. 2024 Oct;
11(3):364-370.
PMID: 39479725
Objective: To evaluate the development of anti-drug antibodies (ADAb) against tumor necrosis factor inhibitors (TNFi) therapy during a 2-year period and search the factors linked to patients with axial spondyloarthritis...
5.
Hatemi G, Seyahi E, Fresko I, Talarico R, Ucar D, Hamuryudan V
Clin Exp Rheumatol
. 2024 Oct;
42(10):1999-2007.
PMID: 39404479
The aim of this review is to provide a critical summary of studies published during 2023 that contribute to our understanding of Behçet's syndrome. An increase in the incidence of...
6.
Nas E, Caliskan E, Gulec Z, Uygunoglu U, Tutuncu M, Saip S, et al.
J Neurol
. 2024 Sep;
271(10):6903-6911.
PMID: 39230724
Objectives: We aimed to identify conditions mimicking nervous system involvement among patients with Behçet's syndrome (BS) and to determine clinical, laboratory and imaging findings that may help in the differential...
7.
Esatoglu S, Sonmez O, Ucar D, Kaymaz E, Ozguler Y, Ugurlu S, et al.
Rheumatology (Oxford)
. 2024 Aug;
PMID: 39110537
Objectives: Treatment response may be variable across organ manifestations of Behçet syndrome (BS). We aimed to determine the frequency of de novo manifestations during adalimumab treatment. Methods: We conducted a...
8.
Ucar D, Bircan B, Rustamli N, Batu Oto B, Hamuryudan V, Hatemi G, et al.
Ocul Immunol Inflamm
. 2024 Jul;
33(2):243-249.
PMID: 39079032
Purpose: The prognostic importance of vitreous cells (VC) in patients with Behçet syndrome (BS) is unknown. We aimed to determine the frequency of developing posterior uveitis (PU) and any additional...
9.
Ozdede A, Esatoglu S, Durmaz E, Karakoc A, Ogun H, Hatemi G, et al.
Clin Exp Rheumatol
. 2024 Jul;
42(10):2057-2064.
PMID: 38976306
Objectives: Tocilizumab has been increasingly reported as an alternative therapeutic agent in the management of Behçet's syndrome (BS) and it has been mostly tried in BS patients with neurological and...
10.
Ozyazgan Y, Ucar D, Batu Oto B, Esatoglu S, Ozguler Y, Hatemi G, et al.
Ocul Immunol Inflamm
. 2024 May;
32(10):2332-2338.
PMID: 38768092
Introduction/objective: There is currently no tool available to assess the severity of damage in uveitis due to Behçet's syndrome (BS). In this preliminary study, we developed a new grading system...